Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study.
We treated nine patients in first remission from AML with rhIL-2. The toxic effects of rhIL-2 infusion were, malaise, pyrexia, and hypotension, which resolved rapidly on cessation of rhIL-2 infusion. No patient required transfer to an intensive care unit. Following rhIL-2 infusions patients developed eosinophilia, and a modest lymphocytosis, involving both NK cells, and T lymphocytes. Relapse occurred in six patients at a median of 39 weeks from remission. A particular concern was rapid relapse in the two patients with AML FAB type M5. There was no survival advantage from rhIL-2 treatment when compared to a similar group of chemotherapy only treated AML patients from this institution.
Macdonald
D
D
Department of Haematology, Royal Postgraduate Medical School, Hammersmith Hospital, London, U.K.
Jiang
Y Z
YZ
Gordon
A A
AA
Mahendra
P
P
Oskam
R
R
Palmer
P A
PA
Franks
C R
CR
Barrett
A J
AJ
D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D005260:Female; D005334:Fever / Q000209:etiology; D006801:Humans; D007022:Hypotension / Q000209:etiology; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D016131:Lymphocyte Subsets; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate
D007376:Interleukin-2; D011994:Recombinant Proteins